Logo do repositório
 
Publicação

The blood-brain barrier in brain metastasization of breast cancer : a source of biomarkers, a target for modulation, and an obstacle to overcome

2024-07Tese de doutoramento Acesso embargado
Ver registo simples
datacite.subject.fosCiências Naturais::Ciências Biológicaspt_PT
dc.contributor.advisorBrito, Maria Alexandra de Oliveira Silva Braga Pedreira de
dc.contributor.advisorVideira, Mafalda de Castro Ascensão Marques
dc.contributor.advisorCarvalheiro, Manuela Colla
dc.contributor.authorPereira, Joana
dc.date.accessioned2025-02-07T17:30:37Z
dc.date.embargo2028-02
dc.date.issued2024-07
dc.date.submitted2024-04
dc.description.abstractAs of 2020, breast cancer (BC) has become the leading cause of neoplastic disease worldwide, with an estimated 3 million new cases, and projections indicate that it will result in 1 million fatalities by 2040. An alarming concern of this disease is its metastatic stage, responsible for most BC deaths. Among all BC subtypes, triple-negative BC (TNBC) stands out as the most aggressive with a poor prognosis. It is also particularly susceptible to developing brain metastases. BC brain metastases (BCBM) leave patients with limited treatment options and extremely low survival rates, due to lack of a timely diagnose owing to the absence of biomarkers, while blood-brain barrier (BBB) restricts most drugs’ brain access. Thus, it is crucial to understand the mechanism involved in the interaction between BBB endothelial cells and breast cancer cells (BCCs) prior to brain metastases formation, as well as the identification of early biomarkers of this process. Additionally, new therapeutics addressing BCCs extravasation process and eradicate BCBM should be investigated. This thesis stands out due to its multifaceted approach, which includes the 1) investigation of the key molecules involved in the interaction between BBB endothelial cells and BCCs during BCBM development; 2) identification of circulating biomarkers indicative of BCBM development, with potential diagnostic and prognostic value, utilizing liquid biopsy; 3) uncover molecules capable of preserving the BBB during extravasation, aiming to impede the transendothelial migration (TEM) of BCCs as a preventive measure; 4) and explore novel treatment strategies, such as the co-administration of a cytotoxic drug and a small interfering RNA (siRNA) to abrogate the already established BCBM. Firstly, the players involved in TNBC cells (4T1 cell line) extravasation, as well as its temporal and spatial profile were disclosed in vivo and in vitro. Key mechanisms such as paracellular and transcellular BBB permeability, cell communication, cytoskeleton remodelling, proliferative and migratory BCC´s properties accompanied with invadopodium formation were revealed. Moreover, brain microvascular endotelial-derived extracellular vesicles and specific microRNAs (miR) were identified as biomarkers of advanced and precocious stages of BCBM, respectively. Secondly, given the altered BBB permeability upon BCCs contact, a preventive strategy was explored aiming the improvement of BBB’ properties. A high-throughput microscopy screening was performed on a library of new and already approved drugs to assess their ability to preserve BBB properties and prevent BCCs from adhering and migrating across the endothelium. Among the tested drugs, minocycline hydrochloride (MH) was the most promising in preventing BBB disruption and 4T1 cells migration, thus rising as a potential modulator of BBB integrity preservation. To minimize side effects and ensure specific BBB-delivery, a trojan horse drug carrier approach was employed targeting the transferrin receptor (TfR), which is highly expressed in brain microvascular endothelial cells, using the RI7217 (Ri7), an anti-TfR antibody. A transferrin receptor-targeted liposome (Lip) carrying MH (Ri7-MH-Lip) was developed and characterized. Ri7-MH-Lip disclosed increased cellular uptake via clathrin-dependent pathway, with no endothelial safety concerns. The Ri7-MH-Lip treatment not only reduced in vitro BCC-induced junctional protein disruption but also decreased endothelial matrix metalloproteinase 9 (MMP-9) overexpression. Additionally, it hampered BCCs’ adhesion to the endothelial monolayer via downregulation of endothelial vascular cell adhesion molecule 1. Ri7-MH-Lip also showed a safe and efficient outcome in vivo. No alteration in the enzymes associated with cardiac, renal, and hepatic toxicity was observed. Moreover, a reduction in BCBM was demonstrated, with the decrease of paracellular permeability and immune-cell infiltration. Furthermore, modulation of circulant miR-802-5p and miR-194-5p expression revealed their potential to be used as biomarkers of therapeutic response. Finally, given the persistent expression of platelet-derived growth factor subunit B (PDGF-B) in BCCs during the formation of brain metastases, coupled with the absence of specific therapies for this pathology, there is a pressing need for new therapeutic strategies. This thesis unveiled the potential of a BBB-permeant dual therapeutic strategy for the delivery of a cytotoxic molecule [salinomycin - SAL] and siRNA therapy [anti-PDGF-B - siPDGF-B] to induce BCBM eradication. Stable nucleic acid lipid particle (SNALP) for encapsulating siPDGF-B, as well as liposomes for incorporating SAL were developed and characterized. Both were conjugated with chlorotoxin (CTX) for to specifically target BCCs. The resulting formulations are denoted as CTX-siPDGF-B-SNALP and CTX-SAL-Lip, respectively. The co-administration of these systems in vitro inhibited BCCs’ proliferation (Ki-67) while the application of each formulation individually led to cell senescence in both cases. The formulations did not affect endothelial viability, although SAL liposomes impaired BBB integrity. In vivo, treatment with siPDGF-B lipid particles effectively reduced both the number of metastases and the levels of PDGF-B and Ki-67. In conclusion, this study has unveiled the cellular and molecular processes involved in BCBM formation, it has also revealed how preventive and therapeutic strategies influence the pathological events associated with disease development. Notably, miR-802 and miR-194 have emerged as valuable diagnostic and prognostic biomarkers. While this study is merely the tip of the iceberg, it introduces exciting possibilities. It suggests repurposing MH as a preventive therapeutic approach and utilizing siPDGF-B as treatment. These findings pave the way for the development of personalized pharmacological strategies to combat this illness.pt_PT
dc.description.provenanceSubmitted by Paula Guerreiro (passarinho@reitoria.ulisboa.pt) on 2025-02-03T16:15:04Z No. of bitstreams: 1 scnd990026354742087_td_Joana_Pereira.pdf: 10030654 bytes, checksum: 2de307945a2846c56e6b268115a2eee6 (MD5)en
dc.description.provenanceMade available in DSpace on 2025-02-07T17:30:37Z (GMT). No. of bitstreams: 1 scnd990026354742087_td_Joana_Pereira.pdf: 10030654 bytes, checksum: 2de307945a2846c56e6b268115a2eee6 (MD5) Previous issue date: 2024-07en
dc.identifier.tid101676280pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.5/98226
dc.language.isoengpt_PT
dc.relationThe blood-brain barrier in brain metastasization of breast cancer: a source of biomarkers, a target for modulation and an obstacle to overcome
dc.subjectAbordagens terapêuticas preventivas e de tratamentopt_PT
dc.subjectBarreira hematoencefálicapt_PT
dc.subjectBiomarcadores circulantespt_PT
dc.subjectmetástases encefálicas de cancro da mamapt_PT
dc.subjectSistemas dirigidos de veiculação de moléculaspt_PT
dc.subjectBlood-brain barrierpt_PT
dc.subjectbreast cancer brain metastasespt_PT
dc.subjecttargeted-drug delivery systemspt_PT
dc.subjectpreventive and treatment therapeutic approachespt_PT
dc.subjectcirculating biomarkerspt_PT
dc.titleThe blood-brain barrier in brain metastasization of breast cancer : a source of biomarkers, a target for modulation, and an obstacle to overcomept_PT
dc.typedoctoral thesis
dspace.entity.typePublication
oaire.awardNumberSFRH/BD/145522/2019
oaire.awardNumberPTDC/MED-ONC/29402/2017
oaire.awardNumberUIDP/04138/2020
oaire.awardNumberUIDB/04138/2020
oaire.awardTitleThe blood-brain barrier in brain metastasization of breast cancer: a source of biomarkers, a target for modulation and an obstacle to overcome
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F145522%2F2019/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FMED-ONC%2F29402%2F2017/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/Concurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017%2F2018) - Financiamento Programático/UIDP%2F04138%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/Concurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017%2F2018) - Financiamento Base/UIDB%2F04138%2F2020/PT
oaire.fundingStream3599-PPCDT
oaire.fundingStreamConcurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017/2018) - Financiamento Programático
oaire.fundingStreamConcurso de avaliação no âmbito do Programa Plurianual de Financiamento de Unidades de I&D (2017/2018) - Financiamento Base
person.familyNamePereira
person.givenNameJoana
person.identifier.ciencia-idC913-1CF6-111E
person.identifier.orcid0000-0002-8219-6240
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsembargoedAccesspt_PT
rcaap.typedoctoralThesispt_PT
relation.isAuthorOfPublication6b5a8f46-bc5b-4d13-bd9d-00c069fca899
relation.isAuthorOfPublication.latestForDiscovery6b5a8f46-bc5b-4d13-bd9d-00c069fca899
relation.isProjectOfPublicationd2ccb1b1-986b-4532-96da-482b65156b8d
relation.isProjectOfPublication72acd25f-6a24-4cae-bd58-4a69dee69dc6
relation.isProjectOfPublication7c535e6f-bffe-4efa-90cf-7a4c2f952889
relation.isProjectOfPublicationa8ffc838-403a-44b2-9239-5f8f779a39a1
relation.isProjectOfPublication.latestForDiscovery72acd25f-6a24-4cae-bd58-4a69dee69dc6
thesis.degree.nameTese de doutoramento, Farmácia (Biologia Celular e Molecular), Universidade de Lisboa, Faculdade de Farmácia, 2024pt_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
scnd990026354742087_td_Joana_Pereira.pdf
Tamanho:
9.57 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções